Clinical Trial

A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a multicenter, randomized, open-label, phase 3 clinical study to evaluate the efficacy of SHR-A1912 combined with R-GemOx in relapsed refractory diffuse large B-cell lymphoma.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-04-08; most recent amendment 2026-06-29.
Status change: Not Yet Recruiting → Recruiting 2025-05-12
Trial Details
NCT Number NCT06929624
Lead Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions Diffuse Large B-cell Lymphoma
Enrollment 280 participants
Start Date 2025-04-24
Primary Completion 2027-03 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-01